KCNJ10 and myeloid sarcoma: Using the same peptide-based ELISA and immunostaining, Brickshawana et al. detected reactivity to KIR4.1 in the sera of 3 (<1%) of 268 patients with MS, and 2 (<1%) of 208 HCs [41].